TCL Archive RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment September 27, 2013
TCL Archive A Message From NCI: “We Deeply Regret The Need To Eliminate This Program.” AP4 Applicants And Corporate Partners Spent Years, Money, Before NCI Pulled The Plug On Novel Public-Private Partnerships. Von Eschenbach Called AP4 “A New Paradigm” For Drug Development. NCI Executive Committee “Prioritized” Programs. April 21, 2006
TCL Archive Also in this 8-page issue: FDA begins search for director of new Office of Oncology Drug Products. October 8, 2004
